Yubin Zhou, a leading researcher at the Institute of Biosciences and Technology's Center for Translational Cancer Research, is pioneering groundbreaking studies at the cellular and genetic levels. With over 180 scientific publications to his name, Zhou employs advanced technologies such as CRISPR and chemogenetic systems to unravel complex diseases.
Chemogenetics is a novel approach that manipulates cell behavior using small external molecules, including medications and dietary compounds, to activate engineered switches within targeted cells. Unlike traditional drugs that impact various tissues, this method specifically targets programmed cells.
Caffeine's Role in Gene Editing
Zhou's recent research expands on previous findings regarding genetic switches. His team has created a new chemogenetic system that combines CRISPR with caffeine, allowing precise control over gene editing. The process begins by preparing cells through established gene transfer techniques, introducing genes that produce three essential components: a nanobody, its corresponding target protein, and the CRISPR machinery. Once these components are inside the cell, they are naturally produced. The system is activated externally; consuming approximately 20 mg of caffeine--found in coffee, chocolate, or soda--triggers the nanobody and protein to bind, activating CRISPR to make specific gene modifications.
This innovative strategy also enables the activation of T cells, which serve as the immune system's memory, allowing the body to respond swiftly to past infections. By intentionally activating these cells, researchers gain a powerful new tool to direct immune responses against specific diseases.
A Reversible Gene Switch
Importantly, the research team discovered that certain drugs can reverse this process. These drugs separate the paired proteins, halting further gene editing. This level of control is crucial for developing safe and adjustable chemogenetic therapies. In clinical settings, physicians could temporarily pause gene activity if a patient experiences side effects, resuming it later when conditions improve.
Zhou explains, "You can also engineer these antibody-like molecules to work with rapamycin-inducible systems, achieving the opposite effect by adding a different drug." Rapamycin, an established immunosuppressant, is a strong candidate for this innovative system due to its affordability and common usage.
Caffebodies and Future Therapies
The team refers to the engineered nanobodies that respond to caffeine as "caffebodies." Zhou envisions these caffebodies as potential treatments for various diseases, suggesting that in the future, individuals with diabetes might boost insulin production simply by enjoying a cup of coffee.
Beyond insulin, this platform can be adapted to regulate other vital molecules, including those that manage T cells. In cancer therapy, caffebodies could be integrated into T cells, allowing physicians to control how and when the immune system targets tumors.
In animal studies, caffeine and its metabolites, such as theobromine from chocolate, successfully triggered this gene editing response. Zhou emphasizes that this method is accessible, manageable, and may lead to fewer side effects compared to existing therapies.
Precision in Gene and Cell Therapy
While previous attempts to activate gene editing with small molecules exist, this system provides enhanced control. After caffeine is administered, researchers have a limited timeframe to guide gene editing before rapamycin acts as a stop signal, ending the activity. This coordinated regulation is rare in current technologies, making it particularly promising for research and therapeutic applications.
"It's quite modular," Zhou notes, highlighting the system's adaptability for CRISPR and CAR-T cells. The team aims to advance preclinical testing and explore further medical applications for caffebodies and CRISPR, moving towards a future where familiar compounds contribute to advanced precision medicine.
"We are excited about repurposing well-known drugs like caffeine to enable new applications," Zhou concludes, envisioning a future where simple, familiar substances can finely tune effective therapies safely and reversibly.
